ERBB2 and breast cancer: In our study; patients ≥60 years of age were more likely to treated with paclitaxel+T, while those <60 years patients were more likely to receive docetaxel cyclophosphamide + T. The APT trial[14] (including 192 patients with pT1a-b pN0 HER2-positive breast cancer, 33.7% patients older than 60 years and 10.1% patients ≥70 years old) demonstrated that paclitaxel for 12 weeks with trastuzumab was well-tolerated, with an incidence of grade 3 to 4 LVSD (congestive heart failure CHF) of only 0.5% (95% CI, 0.1–1.8).